Olema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer Symposium
Key Highlights
- ➤Olema will present OP-3136 plus fulvestrant Phase 1b/2 data at SABCS
- ➤Palazestrant plus everolimus Phase 1b/2 data scheduled for December 10 presentation
- ➤Palazestrant plus atirmociclib Phase 1b data scheduled for December 11 presentation
- ➤Palazestrant is being evaluated in two ongoing pivotal Phase 3 trials
- ➤OP-3136 Phase 1 enrollment is ongoing after FDA IND clearance in December 2024
SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present clinical data from the Phase 1b/2 study of OP-3136 in combination with fulvestrant, the Phase 1b/2 study of palazestrant in combination with everolimus, and the Phase 1b study of palazestrant in combination with atirmociclib in poster presentations at the San Antonio Breast Cancer Symposium (SABCS) taking place December 8-11 in San Antonio, TX.
Poster Presentation Details Title: A phase 1 study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy and in combination with endocrine therapy (ET) in estrogen receptor-positive (ER+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC) Abstract Number: 3363 Presentation Number: P1-4-16 Date/Time: Wednesday, December 9, 2026, 12:30 PM – 2:00 PM CT/11:30 AM – 1:00 PM ET
Get started
Create a free account to read the full story.